Galena Biopharma, Inc. (GALE) shares are up $0.12, or 6%, to $2.12 in after-hours trading Thursday after the company reported its fourth quarter 2014 earnings results.
The biopharmaceutical firm reported earnings of ($0.06) per share on revenues of $3.2 million, up 142.6% from a year ago. Analysts were expecting EPS of ($0.11) on revenues of $2.58 million.
For full-year 2014, the company reported net revenue of $9.3 million, compared $2.5 million for the same period of 2013.
On valuation measures, Galena Biopharma Inc. shares, which currently have an average 3-month trading volume of 1.57 million shares, trade with a price-to-sale ratio of 31.83. The median Wall Street price target on the name is $6.50 with a high target of $8.00. Currently ticker boasts 6 ‘Buy’ endorsements, compared to 1 ’Hold’ and 1 ‘Sell’.
Profitability-wise, GALE has a t-12 operating margin of (714.82%). The $242.91 million market cap company reported $23.7 million in cash vs. $43,429 in total liabilities in its most recent quarter.
GALE currently prints a one year loss of about 51% and a year-to-date return of around 29.15%.
The chart below shows where the equity has traded over the last 52 weeks.
Galena Biopharma, Inc., is a biopharmaceutical company focused on developing oncology treatments that address major unmet medical needs to advance cancer care. The company was founded in 2003 and is based in Lake Portland, Oregon.
- Bulenox: Get 45% to 91% OFF ... Use Discount Code: UNO
- Risk Our Money Not Yours | Get 50% to 90% OFF ... Use Discount Code: MMBVBKSM
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply